Cancers & treatments·Regimen libraryLater line

Cabazitaxel + prednisone

Checked 2026-09-09

Metastatic castration-resistant prostate cancer after docetaxel and an AR-pathway inhibitor

One cycle

every 21 days

21-day cycle, until progression (up to 10)IntravenousOral Daily oral course

Components

Drug	Dose	Route	Days	Note
Cabazitaxel Cytotoxic chemotherapy (taxane)	20 mg/m² (25 mg/m² in selected patients)	IV	D1
Prednisone	10 mg once daily	Oral	D1-21

Cycles

until progression (up to 10)

21-day cycle

Emetogenicity

Low (10-30%)

G-CSF

Recommended

Notes

Primary G-CSF prophylaxis is advised at 25 mg/m² and for patients over 65 or with prior febrile neutropenia.

Used in

Prostate cancer

Products

Cabazitaxel

Source

CARD, NEJM 2019

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

Docetaxel + prednisone

Metastatic hormone-sensitive (with ADT, 6 cycles: CHAARTED, ARASENS) or castration-resistant prostate cancer

every 21 days × 6

Abiraterone + prednisone with ADT

High-risk metastatic hormone-sensitive (LATITUDE, STAMPEDE) or castration-resistant prostate cancer

every 28 days

177Lu-PSMA-617

PSMA PET-positive metastatic castration-resistant prostate cancer after an AR-pathway inhibitor (PSMAfore) and, in VISION, after taxane

every 42 days × 6

Olaparib maintenance

Newly diagnosed BRCA-mutant advanced ovarian cancer after platinum response (2 years); recurrent platinum-sensitive disease; BRCA/HRR-mutant prostate; germline BRCA pancreatic after platinum

every 28 days × 2

All regimens Abiraterone + prednisone with ADT →